Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of Apatinib plus Temozolomide in Treating Recurrent Malignant Brain Glioma.

African health sciences·2025
Same author

A Review of Joining Technologies for SiC Matrix Composites.

Materials (Basel, Switzerland)·2025
Same author

Telangiectatic osteosarcoma of the thoracic vertebra: a case report and literature review.

Frontiers in oncology·2025
Same author

Validation of a Novel Computational Fluid Dynamics Based Method for Assessing Intracoronary Flow: Combining Coronary Angiography and Fractional Flow Reserve.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2025
Same author

Prospective Study Comparing [<sup>99m</sup>Tc]Tc-DP-FAPI Quantitative SPECT/CT with [<sup>68</sup>Ga]Ga-FAPI-04 PET/CT in Patients with Gastrointestinal Tumors.

Molecular pharmaceutics·2024
Same author

Assessment of myocardial injury by SPECT myocardial perfusion imaging in patients with COVID-19 infection in a single center after lifting the restrictions in China.

Annals of nuclear medicine·2024
Same journal

Enhanced pre-therapy dosimetry for SSTR PET: A head-to-head preclinical assessment of [<sup>89</sup>Zr]Zr-DFO-TOC and [<sup>89</sup>Zr]Zr-DFO-TATE.

Nuclear medicine and biology·2026
Same journal

Pharmacokinetics and dosimetry of radiolabeled FAP-targeting single-domain antibody 4AH29 in Göttingen minipigs.

Nuclear medicine and biology·2026
Same journal

Comparative intra-articular retention of [<sup>177</sup>Lu]Lu-MAA and <sup>90</sup>Y resin in a rat knee model.

Nuclear medicine and biology·2026
Same journal

Evaluating the tumour detection efficacy of [<sup>18</sup>F]Fluorthanatrace positron emission tomography in a metastatic lung cancer animal model.

Nuclear medicine and biology·2026
Same journal

Development of a pyrogallol-formaldehyde resin column for one-step pre-purification of <sup>68</sup>Ge/<sup>68</sup>Ga generator eluates: Enhanced [<sup>68</sup>Ga]Ga-DOTA-TATE radiolabeling yield by selective removal of tetravalent cationic impurities.

Nuclear medicine and biology·2026
Same journal

[<sup>68</sup>Ga]Ga-NOTA-ATH001 positron emission tomography as a general tool for non-invasive detection of platelet derived growth factor receptor beta in mesenchymal cells.

Nuclear medicine and biology·2026
See all related articles

Related Experiment Video

Updated: Jun 14, 2026

A New Toolkit for Evaluating Gene Functions using Conditional Cas9 Stabilization
08:20

A New Toolkit for Evaluating Gene Functions using Conditional Cas9 Stabilization

Published on: September 2, 2021

Combination therapy in A549 cells.

Menghui Yuan1, Jing Wang, Jinglan Deng

  • 1Department of Nuclear Medicine, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.

Nuclear Medicine and Biology
|March 30, 2010
PubMed
Summary
This summary is machine-generated.

This study combined a radiotherapeutic agent (131)I-RC-160 with 5-FC prodrug in engineered lung cancer cells. The combination therapy significantly inhibited tumor growth, offering a potential new strategy for lung cancer treatment.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Related Experiment Videos

Last Updated: Jun 14, 2026

A New Toolkit for Evaluating Gene Functions using Conditional Cas9 Stabilization
08:20

A New Toolkit for Evaluating Gene Functions using Conditional Cas9 Stabilization

Published on: September 2, 2021

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy

Background:

  • Investigating novel therapeutic strategies for non-small cell lung cancer (NSCLC).
  • Utilizing gene engineering to enhance targeted cancer therapy.
  • Exploring the synergistic effects of combined treatment modalities.

Purpose of the Study:

  • To evaluate the anti-tumor efficacy of combining (131)I-RC-160 and 5-FC in NSCLC.
  • To assess the co-expression of human somatostatin receptor 2 (hSSTR2) and cytosine deaminase (CD) genes in A549 cells.
  • To determine the in vivo targeting and therapeutic effects of this combined approach.

Main Methods:

  • Stable transfection of A549 cells with hSSTR2 and CD genes.
  • Verification of gene expression using RT-PCR, Western blot, flow cytometry, and immunofluorescence.
  • In vivo biodistribution studies of (99m)Tc-RC-160 in tumor-bearing mice.
  • Assessment of tumor growth inhibition and immunohistochemical analysis post-treatment.

Main Results:

  • Successful co-expression of hSSTR2 and CD in engineered A549 cells.
  • Specific in vivo targeting of (131)I-RC-160 to tumors expressing hSSTR2.
  • Significantly enhanced tumor inhibition in the combination therapy group compared to single-agent or control groups.

Conclusions:

  • Co-expression of hSSTR2 and CD sensitizes NSCLC cells to combined (131)I-RC-160 and 5-FC therapy.
  • This dual-gene engineered approach demonstrates a promising therapeutic strategy for lung cancer.
  • The findings support the potential of targeted radionuclide therapy combined with prodrugs for improved cancer treatment outcomes.